Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

1.220 -0.060 (-4.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ALX Oncology Holdings Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development 
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces November Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
ALX Oncology Holdings Inc. (NASDAQ: ALXO) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational CD47 blocker, in combination with zanidatamab, an investigational dual... 
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal antibody in patients with multiple myeloma 
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Appoints Allison Dillon as Chief Business Officer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces November Investor Conference Participation
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Pricing of Public Offering
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology Announces Proposed Public Offering
From ALX Oncology
Via GlobeNewswire
ALX Oncology Holdings Inc. (NASDAQ: ALXO) is One of Tuesday Morning’s Most Active Stocks
Via Investor Brand Network
News headline image
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
From ALX Oncology
Via GlobeNewswire
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.